Leaflet LAMIVUDINA/ZIDOVUDINA AUROBINDO 150mg / 300mg film-coated tablets


Indicated for: HIV-1 infection

Substance: lamivudine + zidovudine (nucleoside/nucleotide reverse transcriptase inhibitors)

ATC: J05AR01 (Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations)

The combination of lamivudine and zidovudine is used for the treatment of HIV-1 infection. Both substances are antiretrovirals that inhibit viral replication by interfering with reverse transcriptase.

The medication is taken orally, usually twice daily, as directed by a doctor. It is important to follow the treatment regimen to prevent the development of viral resistance.

Side effects may include nausea, anemia, fatigue, or muscle pain. In rare cases, lactic acidosis, myelosuppression, or severe allergic reactions may occur.

This combination is not recommended for patients with severe renal impairment, severe anemia, or hypersensitivity to any of the components.

General data about LAMIVUDINA/ZIDOVUDINA AUROBINDO 150mg / 300mg

  • Substance: lamivudine + zidovudine
  • Date of last drug list: 01-05-2026
  • Commercial code: W70070001
  • Concentration: 150mg / 300mg
  • Pharmaceutical form: film-coated tablets
  • Quantity: 60
  • Product type: generic
  • Price: 437.62 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: APL SWIFT SERVICES (MALTA) LIMITED - MALTA
  • Holder: AUROBINDO PHARMA (MALTA) LIMITED - MALTA
  • Number: 10381/2017/01
  • Shelf life: 4 years

Combinations with other substances

Compensation lists for LAMIVUDINA/ZIDOVUDINA AUROBINDO 150mg / 300mg Aurobindo

NHP 1.A (C2) - People with HIV/AIDS and post-exposure treatment

Price

Copayment

Patient

437.62 RON

437.62 RON

0.00 RON